Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) Target Price at $19.70

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has received a consensus recommendation of “Hold” from the thirteen brokerages that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, four have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $19.70.

A number of equities research analysts recently commented on the company. Weiss Ratings upgraded Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 2nd. BTIG Research cut shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. B. Riley Financial decreased their price objective on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Finally, Morgan Stanley reaffirmed an “underweight” rating and issued a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a report on Friday, May 15th.

Institutional Investors Weigh In On Aardvark Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. UBS Group AG raised its stake in shares of Aardvark Therapeutics by 5.4% during the 3rd quarter. UBS Group AG now owns 54,728 shares of the company’s stock valued at $727,000 after buying an additional 2,804 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Aardvark Therapeutics during the second quarter worth about $42,000. Bank of America Corp DE grew its holdings in Aardvark Therapeutics by 72.9% during the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after acquiring an additional 3,369 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Aardvark Therapeutics during the fourth quarter valued at approximately $47,000. Finally, Persistent Asset Partners Ltd purchased a new position in Aardvark Therapeutics during the fourth quarter valued at approximately $56,000.

Aardvark Therapeutics Stock Performance

Shares of AARD opened at $6.33 on Friday. The stock has a 50-day moving average of $4.81 and a two-hundred day moving average of $7.58. The stock has a market cap of $138.50 million, a P/E ratio of -1.97 and a beta of 3.93. Aardvark Therapeutics has a one year low of $3.35 and a one year high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.99) earnings per share for the quarter. Analysts predict that Aardvark Therapeutics will post -3.46 EPS for the current fiscal year.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (ROR?). ROR? plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective ROR? inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.